U.S. Markets closed

Prima BioMed awarded Japanese patent for CVac

Prima BioMed announced that it has been granted a patent from the Japanese Patent Office that protects methods used in the manufacture of CVac. The method of use claims secured in patent number 5192020 entitled "Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen" provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein conjugated to an antigen, including but not limited to mucin 1.